FR13C0034I2 - Derives de styrylpyridine et leurs applications a la liaison et a l'imagerie de plaques amyloides - Google Patents

Derives de styrylpyridine et leurs applications a la liaison et a l'imagerie de plaques amyloides

Info

Publication number
FR13C0034I2
FR13C0034I2 FR13C0034C FR13C0034C FR13C0034I2 FR 13C0034 I2 FR13C0034 I2 FR 13C0034I2 FR 13C0034 C FR13C0034 C FR 13C0034C FR 13C0034 C FR13C0034 C FR 13C0034C FR 13C0034 I2 FR13C0034 I2 FR 13C0034I2
Authority
FR
France
Prior art keywords
imaging
applications
amyloid plaque
styrylpyridine
plaque binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR13C0034C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of FR13C0034I1 publication Critical patent/FR13C0034I1/fr
Application granted granted Critical
Publication of FR13C0034I2 publication Critical patent/FR13C0034I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR13C0034C 2006-03-30 2013-06-26 Derives de styrylpyridine et leurs applications a la liaison et a l'imagerie de plaques amyloides Active FR13C0034I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78715606P 2006-03-30 2006-03-30
PCT/US2007/007400 WO2007126733A2 (en) 2006-03-30 2007-03-26 Styrylpyridine derivatives and their use for binding and imaging amyloid plaques

Publications (2)

Publication Number Publication Date
FR13C0034I1 FR13C0034I1 (enExample) 2013-08-09
FR13C0034I2 true FR13C0034I2 (fr) 2014-03-07

Family

ID=38326579

Family Applications (1)

Application Number Title Priority Date Filing Date
FR13C0034C Active FR13C0034I2 (fr) 2006-03-30 2013-06-26 Derives de styrylpyridine et leurs applications a la liaison et a l'imagerie de plaques amyloides

Country Status (35)

Country Link
US (3) US7687052B2 (enExample)
EP (3) EP2363391A1 (enExample)
JP (1) JP5290954B2 (enExample)
KR (1) KR101376807B1 (enExample)
CN (1) CN101522624B (enExample)
AT (1) ATE539060T1 (enExample)
AU (1) AU2007243712B2 (enExample)
BE (1) BE2013C044I2 (enExample)
BR (1) BRPI0710225B1 (enExample)
CA (1) CA2644530C (enExample)
CR (1) CR10329A (enExample)
CY (3) CY1113048T1 (enExample)
DK (2) DK2363392T3 (enExample)
EA (1) EA017898B1 (enExample)
EC (1) ECSP088783A (enExample)
ES (2) ES2628882T3 (enExample)
FR (1) FR13C0034I2 (enExample)
GT (1) GT200800201A (enExample)
HR (2) HRP20120135T1 (enExample)
HU (2) HUE032660T2 (enExample)
IL (1) IL193567A (enExample)
LT (1) LT2363392T (enExample)
LU (1) LU92232I2 (enExample)
MX (1) MX2008012527A (enExample)
NO (2) NO342090B1 (enExample)
NZ (1) NZ570887A (enExample)
PL (2) PL2363392T3 (enExample)
PT (2) PT1999109E (enExample)
RS (2) RS52222B (enExample)
SG (1) SG173338A1 (enExample)
SI (2) SI1999109T1 (enExample)
TW (1) TWI399366B (enExample)
UA (1) UA97802C2 (enExample)
WO (1) WO2007126733A2 (enExample)
ZA (1) ZA200807955B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2628882T3 (es) * 2006-03-30 2017-08-04 The Trustees Of The University Of Pennsylvania Derivados de estirilpiridina, y su uso para unir y formar imágenes de placas amiloides
EP2172444A4 (en) * 2007-07-04 2010-12-22 Univ Tohoku PET PROBE WITH FLUORO-SUBSTITUTED ALKOXY GROUP AND HYDROXYGRUPPE
JP5603855B2 (ja) 2008-04-04 2014-10-08 アビッド レディオファーマシューティカルズ、インク． 神経変成疾患の放射性薬剤による画像化
KR20110119670A (ko) * 2008-12-31 2011-11-02 애비드 라디오파마슈티컬스, 인크. 토실레이트 전구체로부터 18ｆ―방사성표지된 스티릴피리딘의 합성 및 그로부터의 안정한 약제학적 조성물
CN102471177A (zh) * 2009-07-10 2012-05-23 拜耳医药股份有限公司 低至中压液相色谱在放射性示踪剂纯化中的应用
EP2501696B1 (en) 2009-10-15 2016-12-28 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
CN102762229B9 (zh) * 2009-12-23 2020-12-01 皮拉马影像股份公司 适用于用疏水pet试剂pet成像的配方
WO2011141515A1 (en) 2010-05-14 2011-11-17 Bayer Pharma Aktiengesellschaft Diagnostic agents for amyloid beta imaging
US20140012032A1 (en) * 2010-06-04 2014-01-09 Piramal Imaging Sa Method for production of f-18 labeled amyloid beta ligands
CA2801530C (en) 2010-06-04 2017-09-12 Piramal Imaging Sa Method for production of f-18 labeled amyloid beta ligands
SG185785A1 (en) 2010-06-04 2013-01-30 Piramal Imaging Sa Method for production of f-18 labeled amyloid beta ligand
TWI504414B (zh) 2010-06-04 2015-10-21 Bayer Schering Pharma Ag 生產Ｆ－１８標記之Ａβ配位體之方法
CN101891674B (zh) * 2010-06-24 2012-11-14 山东大学 4-苯乙烯基吡啶类化合物及其制备方法与应用
EP2627361B1 (en) * 2010-10-12 2017-09-20 Mayo Foundation For Medical Education And Research Imaging of meningiomas using phenylbenzothiazole, stilbene, or biphenylalkyne derivatives
US20140079635A1 (en) * 2011-03-30 2014-03-20 Case Western Reserve University Molecular probes for detecting lipid composition
EP2699157B1 (en) 2011-04-21 2018-03-14 The Regents of The University of California Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles
EP2768790A1 (en) 2011-10-19 2014-08-27 Piramal Imaging SA IMPROVED METHOD FOR PRODUCTION OF F-18 LABELED Aß LIGANDS
WO2013173004A2 (en) 2012-04-10 2013-11-21 Lantheus Medical Imaging, Inc. Radiopharmaceutical synthesis methods
JP6099045B2 (ja) * 2013-04-30 2017-03-22 国立大学法人京都大学 トリアゾロピリミジン誘導体化合物
JP2014218454A (ja) * 2013-05-07 2014-11-20 日本メジフィジックス株式会社 スチリルピリジン誘導体化合物
JP6041751B2 (ja) * 2013-05-07 2016-12-14 日本メジフィジックス株式会社 スチリルピリジン誘導体化合物
CN103645254B (zh) * 2013-11-28 2015-01-07 江苏省原子医学研究所 一种Aβ斑块显像剂前体AV45的含量分析方法
SI3143011T1 (sl) 2014-05-13 2021-08-31 F. Hoffmann-La Roche Ag Devterirane heterociklične spojine in njihova uporaba kot kontrastna sredstva
CN107949383B (zh) 2015-08-18 2022-08-23 加利福尼亚大学董事会 用于成像的含氮氧化合物的淀粉样蛋白结合剂
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
CN109400615B (zh) * 2017-08-18 2021-07-16 上海交通大学医学院附属新华医院 一种靶向β-淀粉样蛋白的香豆素类化合物及其制备与应用
CN108299287A (zh) * 2018-01-02 2018-07-20 北京师范大学 与Aβ斑块具有高亲和力的N2S2类吡啶基苯乙烯化合物
CN114805190A (zh) * 2022-06-08 2022-07-29 吉林大学第一医院 一种甲基苯胺类Aβ蛋白显像剂的双柱合成方法
CN120187703A (zh) 2022-11-14 2025-06-20 伊莱利利公司 氟贝他吡前体av-105的多晶型物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000963A1 (fr) * 1990-07-12 1992-01-23 Yoshitomi Pharmaceutical Industries, Ltd. Composes de styryle et leur utilisation comme medicaments
JPH0545875A (ja) * 1991-08-08 1993-02-26 Konica Corp 感光性組成物
US6020436A (en) * 1993-03-09 2000-02-01 The Chromaline Corporation Photosensitive resin composition
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
EP1266884A4 (en) 2000-03-22 2003-04-23 Bf Res Inst Inc IMAGE DIAGNOSIS PROBE, BASED ON SUBSTITUTED AZOBENZOL OR ITS ANALOGA, FOR DISEASES WHICH ARE ATTRIBUTED TO AMYLOID ACCUMULATION, AND MIXTURES CONTAINING THIS IMAGE
US8007954B2 (en) 2000-11-09 2011-08-30 The Trustees Of The University Of Pennsylvania Use of sulfur-containing fuels for direct oxidation fuel cells
JP2002182254A (ja) 2000-12-18 2002-06-26 Fuji Photo Film Co Ltd 非線形光学材料とその製造方法
CN101003526B (zh) * 2001-08-27 2012-02-22 宾夕法尼亚州大学理事会 茋衍生物及其用于结合和成像淀粉样蛋白斑的用途
US7740772B2 (en) 2002-06-06 2010-06-22 The Trustees Of The University Of Pennsylvania Ceramic anodes and method of producing the same
WO2004016271A1 (en) * 2002-08-14 2004-02-26 Axxima Pharmaceuticals Ag Pyrimidones as antiviral agents
JP4482352B2 (ja) 2004-03-11 2010-06-16 本田技研工業株式会社 固体高分子型燃料電池
US7858072B2 (en) * 2004-12-17 2010-12-28 The Trustees Of The University Of Pennsylvania Stilbene derivatives and their use for binding and imaging amyloid plaques
NZ555942A (en) * 2004-12-17 2011-01-28 Univ Pennsylvania Radiolabelled tilbene derivatives and their use for binding and imaging amyloid plaques
US20070031328A1 (en) 2005-06-24 2007-02-08 Kung Hank F Radiolabeled-pegylation of ligands for use as imaging agents
ES2628882T3 (es) 2006-03-30 2017-08-04 The Trustees Of The University Of Pennsylvania Derivados de estirilpiridina, y su uso para unir y formar imágenes de placas amiloides
US20080253967A1 (en) 2007-04-13 2008-10-16 Kung Hank F Halo-Stilbene Derivatives And Their Use For Binding And Imaging Of Amyloid Plaques

Also Published As

Publication number Publication date
PL1999109T3 (pl) 2012-05-31
PT2363392T (pt) 2017-06-15
FR13C0034I1 (enExample) 2013-08-09
US20130129624A1 (en) 2013-05-23
CY1119048T1 (el) 2018-01-10
CA2644530C (en) 2015-05-19
GT200800201A (es) 2009-08-20
EP2363392A1 (en) 2011-09-07
ECSP088783A (es) 2008-10-31
DK2363392T3 (en) 2017-07-03
TWI399366B (zh) 2013-06-21
US8840866B2 (en) 2014-09-23
SG173338A1 (en) 2011-08-29
ES2378785T3 (es) 2012-04-17
HRP20170857T1 (hr) 2017-12-01
IL193567A0 (en) 2009-05-04
US7687052B2 (en) 2010-03-30
NO20084590L (no) 2008-12-29
AU2007243712B2 (en) 2013-01-10
US8506929B2 (en) 2013-08-13
JP2009532349A (ja) 2009-09-10
MX2008012527A (es) 2008-10-14
EP1999109A2 (en) 2008-12-10
SI1999109T1 (sl) 2012-04-30
WO2007126733A3 (en) 2008-03-06
US20080038195A1 (en) 2008-02-14
JP5290954B2 (ja) 2013-09-18
BRPI0710225B1 (pt) 2021-07-13
AU2007243712A1 (en) 2007-11-08
KR20080106564A (ko) 2008-12-08
RS52222B (sr) 2012-10-31
PT1999109E (pt) 2012-03-16
BE2013C044I2 (enExample) 2026-04-24
NO2018030I1 (no) 2018-09-11
EA017898B1 (ru) 2013-04-30
CN101522624A (zh) 2009-09-02
NZ570887A (en) 2011-05-27
RS56171B1 (sr) 2017-11-30
BRPI0710225A2 (pt) 2011-08-02
DK1999109T3 (da) 2012-04-02
CY1113048T1 (el) 2015-11-04
NO342090B1 (no) 2018-03-19
LU92232I9 (enExample) 2019-01-15
CN101522624B (zh) 2013-11-06
HUS1300028I1 (hu) 2017-08-28
EP2363392B1 (en) 2017-05-03
ATE539060T1 (de) 2012-01-15
LT2363392T (lt) 2017-07-25
HUE032660T2 (en) 2017-10-30
EP2363391A1 (en) 2011-09-07
TW200838852A (en) 2008-10-01
CY2013024I2 (el) 2015-11-04
HRP20120135T1 (hr) 2012-03-31
US20090123369A1 (en) 2009-05-14
UA97802C2 (uk) 2012-03-26
CR10329A (es) 2008-10-29
LU92232I2 (fr) 2013-08-26
WO2007126733A2 (en) 2007-11-08
EA200870389A1 (ru) 2009-04-28
PL2363392T3 (pl) 2017-10-31
ZA200807955B (en) 2012-11-28
CY2013024I1 (el) 2015-11-04
ES2628882T3 (es) 2017-08-04
EP1999109B1 (en) 2011-12-28
KR101376807B1 (ko) 2014-03-20
SI2363392T1 (sl) 2017-09-29
CA2644530A1 (en) 2007-11-08
IL193567A (en) 2014-03-31

Similar Documents

Publication Publication Date Title
LU92232I2 (fr) "Florbétapir (18 F)"
DE60217090D1 (de) Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
MX2007007380A (es) Derivados de estilbeno y su uso para estudios de union y por imagenes de placas amiloides.
MX2008014740A (es) Derivados de 2-arilpirazolo[1,5-alfa]pirimidina-3-il acetamida como ligandos para la proteina translocadora (18 kda).
WO2007130365A3 (en) Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents
NO20090348L (no) Substituerte imidazolonderivater, sammensetninger og anvendelser av samme, samt fremgangsmater for fremstilling av samme
UA99309C2 (ru) Замещенные пиперидинодигидротиенопиримидины
IL196543A (en) Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders
WO2008073350A3 (en) Acetylene derivatives and their use for binding and imaging amyloid plaques
WO2007033080A3 (en) Alzheimer's disease imaging agents
WO2007118963A3 (fr) Composes derives de n-(phenethyl)benzamide substitues, preparation et utilisations
IL194789A0 (en) Terphenyl derivatives for treatment of alzheimer's disease
IL189104A (en) Pharmaceutical preparation containing lasalazide or sodium balasalazide for use in the treatment of gastrointestinal disorders.
EA200970817A1 (ru) Лекарственная форма, содержащая 1{6-[(3-циклобутил-2,3,4,5-тетрагидро-1н-3-бензазепин-7-ил)окси]-3-пиридинил}-2-пирролидинон или его соль и стабилизатор, который уменьшает его деградацию
EP1786467A4 (en) METHOD FOR IMPROVING THE ABSORPTION OF TRANSMOSAL ADMINISTRATIVE FORMULATIONS
WO2006078384A3 (en) Stilbene derivatives and their use
WO2006035157A3 (fr) Composes derives de n- (benzyl) phenylacetamide substitues , preparation et utilisations comme ligands des ppar dans le traitement des dereglements lipidiques et/ou glucidiques
DK1553985T3 (da) Biphenyler som billeddannelsesmiddel i forbindelse med Alzheimers sygdom
ATE461693T1 (de) Verfahren zur behandlung von akuten rhinosinusitis
FR2869615B1 (fr) Derives de l'acide butanoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et leurs applications therapeutiques
HRP20050603A2 (en) Novel anticonvulsant derivative salts
WO2010135493A3 (en) Alzheimer's disease imaging agents
UA91996C2 (ru) Производные стильбена и их применение для связывания и визуализации амилоидных бляшек
ITPD20050015U1 (it) Dospositivo per la consultazione dell'orario ferroviario da parte dei non vedenti